LCI - Lannett Company, Inc.
| Previous Close | 7.15 |
| Open | 7.11 |
| Bid | 7.17 x 800 |
| Ask | 7.20 x 800 |
| Day's Range | 7.06 - 7.37 |
| 52 Week Range | 3.33 - 17.15 |
| Volume | 89,294 |
| Avg. Volume | 1,398,630 |
| Market Cap | 278.543M |
| Beta (3Y Monthly) | 2.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.31 |
| Earnings Date | May 6, 2019 - May 10, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.75 |
- Simply Wall St.•6 days ago
Investors Who Bought Lannett Company (NYSE:LCI) Shares Five Years Ago Are Now Down 77%
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow investors lose their hard-earned money. Anyone who held Lannett Company, Inc. (NYSE:LCI) for five years would...
- Zacks•6 days ago
Are Options Traders Betting on a Big Move in Lannett (LCI) Stock?
Investors need to pay close attention to Lannett (LCI) stock based on the movements in the options market lately.
- Zacks•10 days ago
Lannett (LCI) Gains But Lags Market: What You Should Know
Lannett (LCI) closed at $8.05 in the latest trading session, marking a +0.06% move from the prior day.
- Zacks•14 days ago
Has Lannett Co (LCI) Outpaced Other Medical Stocks This Year?
Is (LCI) Outperforming Other Medical Stocks This Year?
- Zacks•18 days ago
Lannett (LCI) Stock Sinks As Market Gains: What You Should Know
Lannett (LCI) closed at $7.91 in the latest trading session, marking a -0.75% move from the prior day.
- Zacks•25 days ago
Lannett (LCI) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Lannett (LCI) closed at $7.56, marking a +1.2% move from the previous day.
- PR Newswire•26 days ago
Lannett Receives FDA Approval For Aspirin And Extended-Release Dipyridamole Capsules, 25 mg/200 mg
PHILADELPHIA , March 27, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application ...
- PR Newswire•last month
Lannett Purchases $24 Million Of Term Loans In Open Market Transactions
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company's website at www.lannett.com.
- Zacks•last month
Is Lannett Co (LCI) Stock Outpacing Its Medical Peers This Year?
Is (LCI) Outperforming Other Medical Stocks This Year?
- Zacks•last month
Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105
Aerie (AERI) begins dosing in a phase II study on AR-1105 for treating patients with macular edema due to retinal vein occlusion.
- Zacks•last month
Karyopharm Stock Up Even as FDA Delays Selinexor NDA Verdict
Karyopharm's (KPTI) stock rises despite the FDA's decision to delay the verdict on the NDA filing of selinexor, which is developed for treating patients with relapsed-refractory multiple myeloma.
- Zacks•last month
Should Value Investors Consider Lannett Company (LCI) Now?
Let's see if Lannett Company (LCI) stock is a good choice for value-oriented investors right now from multiple angles.
- TheStreet.com•last month
Lannett Rises After Announcing Adderall Distribution Agreement
were rising Monday after the drugmaker announced it was entering an agreement with two other pharmaceutical players to sell a generic form of Adderall. and SunGen Pharma to be the exclusive distributor of a version of Adderall, an amphetamine tablet product. "We expect to launch this generic version of Adderall near term," said Tim Crew, CEO of Lannett.
- Zacks•last month
Late Rally Falls Just Short of Ending Losing Skid
Late Rally Falls Just Short of Ending Losing Skid
- MarketWatch•last month
Lannett shares rise after agreement to sell generic Adderall
Lannett Co. Inc. shares rose 3.1% in Monday premarket trading after the drug company announced an agreement with Elite Pharmaceuticals and SunGen Pharma to distribute a generic form of Adderall. Lannett Chief Executive Tim Crew said in a statement the drug will be available "in the near term." Adderall is used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Under the terms of the agreement, Lannett will provide sales, marketing and distribution support for the drug, receiving a share of the profits in exchange. Adderall, including generic versions, had an estimated market value of $361 million for the year ending January 2019. Lannett's stock has gained 58.5% for the year so far, while the S&P 500 index is up 9.4% for the period.
- PR Newswire•last month
Lannett Enters Into Distribution Agreement For Generic Adderall®
--Company Expects to Commence Marketing the Product Near Term-- PHILADELPHIA , March 11, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with ...
- Zacks•last month
Endo (ENDP) Soars: Stock Adds 6% in Session
Endo (ENDP) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- Zacks•2 months ago
Implied Volatility Surging for Lannett (LCI) Stock Options
Investors need to pay close attention to Lannett (LCI) stock based on the movements in the options market lately.
- Zacks•2 months ago
Top Ranked Value Stocks to Buy for February 27th
Top Ranked Value Stocks to Buy for February 27th
- PR Newswire•2 months ago
Lannett To Participate At Two Investor Conferences In March
PHILADELPHIA , Feb. 26, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences. Schedule below: Raymond James 40th Annual Institutional ...
- Zacks•2 months ago
Top Ranked Value Stocks to Buy for February 20th
Top Ranked Value Stocks to Buy for February 20th
- Moody's•2 months ago
Lannett Company, Inc. -- Moody's announces completion of a periodic review of ratings of Lannett Company, Inc.
Announcement: Moody's announces completion of a periodic review of ratings of Lannett Company, Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Lannett Company, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- Zacks•2 months ago
Top Ranked Value Stocks to Buy for February 12th
Top Ranked Value Stocks to Buy for February 12th
- Benzinga•2 months ago
BMO Capital Markets: Lannett Making Progress With Pipeline, Cost Savings
Lannett Company, Inc. (NYSE: LCI ) reported solid second-quarter results Wednesday and raised its 2019 guidance. The pharma company is making good progress in preparing for the loss of levothyroxine with ...
